Please assess the completion status of the following clinical trial:

Trial Title: Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* histologically confirmed non-clear cell renal cell carcinoma~* confirmed metastatic sites~* no chemotherapy in history~Exclusion Criteria:~* metastases in CNS~* previous targeted therapy~* other tumor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Capecitabine (Type: EXPERIMENTAL): All patients will receive capecitabine.

Based on this trial design, predict the completion outcome and termination type (if applicable).